참고문헌
- Kanis JA: Osteoporosis and osteopenia. J Bone Miner Res 5: 209-211, 1990. https://doi.org/10.1002/jbmr.5650050302
- Kanis JA, Melton LJ 3rd, Christiansen C, Johnston CC, Khaltaev N: The diagnosis of osteoporosis. J Bone Miner Res, 9: 1137-1141, 1994. https://doi.org/10.1002/jbmr.5650090802
- Sambrook P, Cooper C: Osteoporosis. Lancet, 367: 2010-2018, 2006. https://doi.org/10.1016/S0140-6736(06)68891-0
- Wasnich RD, Ross PD, Heilbrun LK, Vogel JM: Prediction of postmenopausal fracture risk with use of bone mineral measurements. Am J Obstet Gynecol, 153: 745-751, 1985.
- Hui SL, Slemenda CW, Johnston CC Jr.: Age and bone mass as predictors of fracture in a prospective study. J Clin Invest, 81: 1804-1809, 1988. https://doi.org/10.1172/JCI113523
- Cummings SR, Black DM, Nevitt MC, et al.: Appendicular bone density and age predict hip fracture in women. The Study of Osteoporotic Fractures Research Group. JAMA, 263: 665-668, 1990. https://doi.org/10.1001/jama.263.5.665
- Gardsell P, Johnell O, Nilsson BE: Predicting fractures in women by using forearm bone densitometry. Calcif Tissue Int, 44: 235-242, 1989. https://doi.org/10.1007/BF02553757
- Cummings SR, Black DM, Nevitt MC, et al.: Bone density at various sites for prediction of hip fractures. The Study of Osteoporotic Fractures Research Group. Lancet, 341: 72-75, 1993. https://doi.org/10.1016/0140-6736(93)92555-8
- Wahner HW: Estimating the risk of osteoporosis. J Nucl Med, 1994;35: 1155-1158.
- Nevitt MC, Johnell O, Black DM, Ensrud K, Genant HK, Cummings SR: Bone mineral density predicts nonspine fractures in very elderly women. Study of Osteoporotic Fractures Research Group. Osteoporos Int, 4: 325-331, 1994. https://doi.org/10.1007/BF01622192
- Carano A, Teitelbaum SL, Konsek JD, Schlesinger PH, Blair HC: Bisphosphonates directly inhibit the bone resorption activity of isolated avian osteoclasts in vitro. J Clin Invest, 85: 456-461, 1990. https://doi.org/10.1172/JCI114459
- Reginster JY, Sarlet N: The treatment of severe postmenopausal osteoporosis: a review of current and emerging therapeutic options. Treat Endocrinol, 5(1): 15-23, 2006. https://doi.org/10.2165/00024677-200605010-00003
- Hochberg MC, Rizzoli R: Long-term experience with alendronate in the treatment of osteoporosis. Expert Opin Pharmacother, 7: 1201-1210, 2006. https://doi.org/10.1517/14656566.7.9.1201
- Madenci E, Yilmaz K, Yilmaz M, Coskun Y: Alendronate treatment in osteogenesis imperfecta. J Clin Rheumatol, 12: 53-56, 2006. https://doi.org/10.1097/01.rhu.0000208490.22492.09
- Sen C, Gunes T, Erdem M, Koseoglu RD, Filiz NO: Effects of calcitonin and alendronate on distraction osteogenesis. Int Orthop, 30: 272-277, 2006. https://doi.org/10.1007/s00264-005-0048-9
- Liel Y: Paget's disease and bisphosphonates. N Engl J Med, 15;353: 2616-2618, 2005. https://doi.org/10.1056/NEJMc052601
- Newman ED, Matzko CK, Olenginski TP, et al.: Glucocorticoid-Induced Osteoporosis Program (GIOP): a novel, comprehensive, and highly successful care program with improved outcomes at 1 year. Osteoporos Int, 17: 1428-1434, 2006. https://doi.org/10.1007/s00198-006-0149-3
- Curtis JR, Westfall AO, Allison JJ, Freeman A, Saag KG: Channeling and adherence with alendronate and risedronate among chronic glucocorticoid users. Osteoporos Int, 17: 1268-1274, 2006. https://doi.org/10.1007/s00198-006-0136-8
- Gass M, Dawson-Hughes B: Preventing osteoporosisrelated fractures: an overview. Am J Med, 119 (4 Suppl 1): S3-S11, 2006.
- Cramer JA, Silverman S: Persistence with bisphosphonate treatment for osteoporosis: finding the root of the problem. Am J Med, 119 (4 Suppl 1): S12-17, 2006.
- Emkey RD, Ettinger M: Improving compliance and persistence with bisphosphonate therapy for osteoporosis. Am J Med, 119 (4 Suppl 1): S18-24, 2006. https://doi.org/10.1016/j.amjmed.2005.12.019
- Penning-van Beest FJ, Erkens JA, Olson M, Herings RM: Loss of treatment benefit due to low compliance with bisphosphonate therapy. Osteoporos Int, 19: 511-517, 2008. https://doi.org/10.1007/s00198-007-0466-1
- Rabenda V, Mertens R, Fabri V, et al.: Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women. Osteoporos Int, 19: 811-818, 2008. https://doi.org/10.1007/s00198-007-0506-x
- Heaney RP, Yates AJ, Santora AC 2nd: Bisphosphonate effects and the bone remodeling transient. J Bone Miner Res, 12: 1143-1151, 1997. https://doi.org/10.1359/jbmr.1997.12.8.1143
- Ravn P, Weiss SR, Rodriguez-Portales JA, et al.: Alendronate in early postmenopausal women: effects on bone mass during long-term treatment and after withdrawal. Alendronate Osteoporosis Prevention Study Group. J Clin Endocrinol Metab, 85: 1492-1497, 2000. https://doi.org/10.1210/jc.85.4.1492
- Baker DE: Alendronate and risedronate: what you need to know about their upper gastrointestinal tract toxicity. Rev Gastroenterol Disord, 2: 20-33, 2002.
- Cramer JA, Amonkar MM, Hebborn A, Altman R: Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin, 21: 1453-1460, 2005. https://doi.org/10.1185/030079905X61875
- Recker RR, Gallagher R, MacCosbe PE: Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clin Proc, 80: 856-861, 2005. https://doi.org/10.4065/80.7.856
- Rizzoli R: Long-term outcome of weekly bisphosphonates. Clin Orthop Relat Res, 443: 61-65, 2006. https://doi.org/10.1097/01.blo.0000200249.12006.6e
- Cooper A, Drake J, Brankin E: the PERSIST Investigators.: Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study. Int J Clin Pract, 60: 896-905, 2006. https://doi.org/10.1111/j.1742-1241.2006.01059.x